Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  AmerisourceBergen    ABC

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

AmerisourceBergen Corp. : AmerisourceBergen Reports $0.62 in Diluted EPS, a 9% Percent Increase, and Revenue of $20.4 Billion for the December Quarter

share with twitter share with LinkedIn share with facebook
share via e-mail
01/26/2012 | 01:05pm CEST

Company Reaffirms Fiscal Year 2012 EPS Guidance Range of $2.74 to $2.84

AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2012 first quarter, ended December 31, 2011, diluted earnings per share were $0.62, a 9 percent increase. Revenue in the quarter was $20.4 billion, up 2 percent. The Company also reaffirmed its expectations for fiscal year 2012 diluted earnings per share in the range of $2.74 to $2.84. All the results are presented in accordance with U.S. generally accepted accounting principles (GAAP).

Fiscal First Quarter Highlights

  • Revenue of $20.4 billion, up 2.4 percent.
  • Diluted earnings per share of $0.62, an 8.8 percent increase.
  • Operating expense ratio of 1.51 percent, down 2 basis points.
  • Operating margin of 1.40 percent, up 1 basis point.
  • Cash flow from operations of $431.7 million.
  • Share repurchases of $128.0 million.

"We are off to a good start in our fiscal year 2012, with December quarter results in line with our expectations, and excellent progress being made on the integration of our recent acquisitions," said Steven H. Collis, AmerisourceBergen President and Chief Executive Officer. "We continued to demonstrate expense and working capital discipline, and our balance sheet remains strong, giving us outstanding financial flexibility."

Results Highlights

  • Revenue: Revenue was $20.4 billion in the first quarter of fiscal 2012, a 2.4 percent increase over the same quarter in the previous fiscal year, driven by a 3.9 percent increase in AmerisourceBergen Specialty Group (ABSG) revenue, and a 2.1 percent increase in AmerisourceBergen Drug Corporation (ABDC) revenue. Strong performance in third party logistics in ABSG and in the retail and institutional segments in ABDC was offset in part by the previously announced loss of a large retail customer. Recent acquisitions, particularly the addition of TheraCom, contributed 0.6 percent of revenue growth in the quarter.
  • Gross Profit: Gross profit in the fiscal 2012 first quarter was $593.1 million, a 2.2 percent increase over the year-ago same period. Gross profit as a percentage of revenue decreased 1 basis point to 2.91 percent over the same period in the previous year. In the same period last year, gross profit of $580.2 million included a non-recurring $12 million benefit in connection with a customer being acquired by a third party, which was offset in the fiscal 2012 quarter by contributions from recent acquisitions. The LIFO charge in the fiscal 2012 first quarter was $3.2 million compared with a $9.9 million charge in the previous year's first quarter.
  • Operating Expenses: For the first quarter of fiscal 2012, operating expenses were $308.2 million compared with $303.5 million in the prior fiscal year's first quarter, a 1.6 percent increase. Operating expenses in the quarter included $3.6 million of acquisition-related transaction expenses. Compared to the prior year, operating expenses as a percentage of revenue in the fiscal first quarter of 2012 were down 2 basis points to 1.51 percent.
  • Operating Income: In the fiscal 2012 first quarter, operating income increased 2.9 percent to $284.9 million, due primarily to the increase in gross profit. Operating income as a percentage of revenue increased 1 basis point to 1.40 percent in the period compared with the previous year's first quarter.
  • Tax Rate: The effective tax rate for the first quarter of fiscal 2012 was 38.2 percent, compared to 38.1 percent in the previous fiscal year's first quarter. We continue to expect our annualized effective tax rate to be approximately 38.4 percent.
  • Earnings Per Share: Diluted earnings per share were up 8.8 percent to $0.62 in the first quarter of fiscal 2012 compared to $0.57 in the previous fiscal year's first quarter. Earnings per share growth exceeded the 1.0 percent growth in net income due to the 6 percent reduction in diluted average shares outstanding.
  • Shares Outstanding: Diluted average shares outstanding for the first quarter of fiscal year 2012 were 263.1 million, down 17.6 million shares from the previous fiscal year's first quarter due primarily to share repurchases, net of option exercises over the last twelve months.

Fiscal Year 2012 Expectations

"Looking ahead, the Company continues to expect diluted earnings per share in fiscal year 2012 to be in the range of $2.74 to $2.84," said Steven H. Collis, AmerisourceBergen President and Chief Executive Officer. "Also unchanged are the assumptions supporting the expected diluted earnings per share range for fiscal year 2012, including: flat to modest revenue growth; operating margin growth in the high single-digit to low double-digit basis points range; and free cash flow in the range of $700 million to $800 million, which includes capital expenditures in the $150 million range. Subject to market conditions, we expect to spend approximately $400 million to repurchase our common shares in fiscal year 2012."

Conference Call

The Company will host a conference call to discuss its results at 11:00 a.m. Eastern Standard Time on January 26, 2012. Participating in the conference call will be: Steven H. Collis, President and Chief Executive Officer; and Michael D. DiCandilo, Executive Vice President and Chief Financial Officer.

To access the live conference call via telephone:

Dial in: The dial-in number for the live call will be 612-332-0226. No access code is needed.

To access the live webcast:

Go to the Investor Relations page at http://www.amerisourcebergen.com.

A replay of the telephone call and webcast will be available from 2:30 p.m. January 26, 2012 until 11:59 p.m. February 2, 2012. The Webcast replay will be available for 30 days.

To access the telephone replay from within the US, dial 800-475-6701. From outside the US, dial 320-365-3844. The access code for the replay is 231917.

To access the archived webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.com.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services companies serving the United States, Canada and selected global markets. Servicing both healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen's service solutions range from pharmacy automation and pharmaceutical packaging to reimbursement and pharmaceutical consulting services. With more than $80 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 11,000 people. AmerisourceBergen is ranked #27 on the Fortune 500 list, and #24 on the Bloomberg Businessweek 50. For more information, go to www.amerisourcebergen.com.

Forward-Looking Statements

Certain of the statements contained in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and change in circumstances. Among the factors that could cause actual results to differ materially from those projected, anticipated or implied are the following: changes in pharmaceutical market growth rates; the loss of one or more key customer or supplier relationships; changes in customer mix; customer delinquencies, defaults or insolvencies; supplier defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and distribution policies or practices; adverse resolution of any contract or other dispute with customers or suppliers; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; qui tam litigation for alleged violations of fraud and abuse laws and regulations and/or any other laws and regulations governing the marketing, sale and purchase of pharmaceutical products or any related litigation, including shareholder derivative lawsuits; changes in federal and state legislation or regulatory action affecting pharmaceutical product pricing or reimbursement policies, including under Medicaid and Medicare; changes in regulatory or clinical medical guidelines and/or labeling for the pharmaceutical products we distribute, including certain anemia products; price inflation in branded pharmaceuticals and price deflation in generics; greater or less than anticipated benefit from launches of the generic versions of previously patented pharmaceutical products; significant breakdown or interruption of our information technology systems; our inability to continue to implement an enterprise resource planning (ERP) system to handle business and financial processes and transactions (including processes and transactions relating to our customers and suppliers) of AmerisourceBergen Drug Corporation operations and our corporate functions as intended without functional problems, unanticipated delays and/or cost overruns; success of integration, restructuring or systems initiatives; interest rate and foreign currency exchange rate fluctuations; economic, business, competitive and/or regulatory developments in Canada, the United Kingdom and elsewhere outside of the United States, including changes and/or potential changes in Canadian provincial legislation affecting pharmaceutical product pricing or service fees or regulatory action by provincial authorities in Canada to lower pharmaceutical product pricing and service fees; the impact of divestitures or the acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control; our inability to successfully complete any other transaction that we may wish to pursue from time to time; changes in tax laws or legislative initiatives that could adversely affect our tax positions and/or our tax liabilities or adverse resolution of challenges to our tax positions; increased costs of maintaining, or reductions in our ability to maintain, adequate liquidity and financing sources; volatility and deterioration of the capital and credit markets; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting our business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2011 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act of 1934.

(In thousands, except per share data)
Three Three
Months Ended Months Ended
December 31, % of December 31, % of %
  2011   Revenue   2010   Revenue Change
Revenue $ 20,360,645 100.00 % $ 19,888,609 100.00 % 2.4 %
Cost of goods sold   19,767,552     19,308,377   2.4 %
Gross profit 593,093 2.91 % 580,232 2.92 % 2.2 %
Operating expenses:
Distribution, selling and administrative 273,865 1.35 % 278,033 1.40 % -1.5 %
Depreciation and amortization 30,755 0.15 % 25,433 0.13 % 20.9 %
Employee severance, litigation and other (1)   3,559   0.02 %   -   - %
Total operating expenses 308,179 1.51 % 303,466 1.53 % 1.6 %
Operating income 284,914 1.40 % 276,766 1.39 % 2.9 %
Other income (1 ) - % (1,667 ) -0.01 %
Interest expense, net   22,591   0.11 %   19,144   0.10 % 18.0 %
Income before income taxes 262,324 1.29 % 259,289 1.30 % 1.2 %
Income taxes   100,208   0.49 %   98,789   0.50 % 1.4 %
Net income $ 162,116   0.80 % $ 160,500   0.81 % 1.0 %
Earnings per share:
Basic $ 0.63 $ 0.58 8.6 %
Diluted $ 0.62 $ 0.57 8.8 %
Weighted average common shares outstanding:
Basic 258,461 275,605
Diluted (2) 263,084 280,693
(1) Represents acquisition costs related to business combinations.
(2) Includes the dilutive effect of stock options, restricted stock, and restricted stock units.
(in thousands)
December 31, September 30,
2011 2011
Current assets:
Cash and cash equivalents $ 2,370,335 $ 1,825,990
Accounts receivable, net 3,724,456 3,837,203
Merchandise inventories 5,824,358 5,466,534
Prepaid expenses and other   36,631   87,896
Total current assets 11,955,780 11,217,623
Property and equipment, net 793,604 772,916
Other long-term assets   3,228,882   2,992,132
Total assets $ 15,978,266 $ 14,982,671
Current liabilities:
Accounts payable $ 9,589,019 $ 9,202,115
Current portion of long-term debt 392,081 392,089
Other current liabilities   1,265,277   1,260,916
Total current liabilities 11,246,377 10,855,120
Long-term debt, less current portion 1,536,939 972,863
Other long-term liabilities 290,351 287,830
Stockholders' equity   2,904,599   2,866,858
Total liabilities and stockholders' equity $ 15,978,266 $ 14,982,671
(in thousands)
Three Three
Months Ended Months Ended
December 31, December 31,
  2011     2010  
Operating Activities:
Net income $ 162,116 $ 160,500

Adjustments to reconcile net income to net cash provided by (used in) operating activities

57,226 61,011
Changes in operating assets and liabilities   212,361     (320,711 )
Net cash provided by (used in) operating activities   431,703     (99,200 )
Investing Activities:
Capital expenditures (48,138 ) (50,091 )
Cost of acquired companies, net of cash acquired   (250,501 )   -  
Net cash used in investing activities   (298,639 )   (50,091 )
Financing Activities:
Net borrowings 563,116 58,401
Purchases of common stock (128,042 ) (185,362 )
Exercises of stock options 16,450 46,982
Cash dividends on common stock (33,708 ) (27,735 )
Debt issuance costs and other   (6,535 )   (282 )
Net cash provided by (used in) financing activities   411,281     (107,996 )
Increase (decrease) in cash and cash equivalents 544,345 (257,287 )
Cash and cash equivalents at beginning of period   1,825,990     1,658,182  
Cash and cash equivalents at end of period $ 2,370,335   $ 1,400,895  

Barbara Brungess, 610-727-7199
[email protected]

© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
04/16Drug suppliers' shares rise as looming Amazon threat appears to ease
04/16Drug suppliers' shares rise as looming Amazon threat appears to ease
04/14CARDINAL HEALTH : Drug CEOs to testify before US Congress
04/13Drug executives to testify about opioid crisis role
04/13AMERISOURCEBERGEN : Nation’s Top Practitioners Address Future of Community..
04/13CARDINAL HEALTH : #SubOversight Announces Hearing to Press Distributors About Ef..
04/12CARDINAL HEALTH : Hearing Marks One-Year of Committee's Bipartisan Investigation
04/10AMERISOURCEBERGEN : Announces Date and Time for Second Quarter Fiscal 2018 Earni..
04/05AMERISOURCEBERGEN CORPORATION (NYSE : ABC) Files An 8-K Departure of Directors o..
04/04AMERISOURCEBERGEN CORP : Change in Directors or Principal Officers (form 8-K)
More news
News from SeekingAlpha
12:48aMr. Market Grasps The Esoteric 
04/19Jelly Beans, Group Think, And Greenblatt's Magic Formula 
04/16CNBC : Amazon kills plan to sell drugs to hospitals 
04/10Big Dividend Growth Does Not Always Mean Big 
Financials ($)
Sales 2018 167 B
EBIT 2018 2 037 M
Net income 2018 1 748 M
Debt 2018 1 008 M
Yield 2018 1,69%
P/E ratio 2018 10,74
P/E ratio 2019 13,42
EV / Sales 2018 0,13x
EV / Sales 2019 0,11x
Capitalization 19 933 M
Duration : Period :
AmerisourceBergen Technical Analysis Chart | ABC | US03073E1055 | 4-Traders
Technical analysis trends AMERISOURCEBERGEN
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 103 $
Spread / Average Target 14%
EPS Revisions
Steven H. Collis Chairman, President & Chief Executive Officer
Tim G. Guttman Chief Financial Officer & Executive Vice President
Dale B. Danilewitz Chief Information Officer & Executive VP
Henry Wadsworth McGee Independent Director
Jane Ellen Henney Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-8.14%66 066